Conatus Pharmaceuticals beats by $0.05, misses on revenue

|About: Conatus Pharmaceuticals (CNAT)|By:, SA News Editor

Conatus Pharmaceuticals (NASDAQ:CNAT): Q2 EPS of -$0.15 beats by $0.05.

Revenue of $8.77M (-12.4% Y/Y) misses by $0.32M.

Press Release

Subscribe for full text news in your inbox